Abstract
Pain affects approximately 80% of patients with pancreatic cancer, with half requiring strong opioid analgesia, namely: morphine-based drugs on step three of the WHO analgesic ladder (as opposed to the weak opioids: codeine and tramadol). The presence of pain is associated with reduced survival. This article reviews the literature regarding pain: prevalence, mechanisms, pharmacological, and endoscopic treatments and identifies areas for research to develop individualized patient pain management pathways. The online literature review was conducted through: PubMed, Clinical Key, Uptodate, and NICE Evidence. There are two principal mechanisms for pain: pancreatic duct obstruction and pancreatic neuropathy which, respectively, activate mechanical and chemical nociceptors. In pancreatic neuropathy, several histological, molecular, and immunological changes occur which correlate with pain including: transient receptor potential cation channel activation and mast cell infiltration. Current pain management is empirical rather etiology-based and is informed by the WHO analgesic ladder for first-line therapies, and then endoscopic ultrasound-guided celiac plexus neurolysis (EUS-CPN) in patients with resistant pain. For EUS-CPN, there is only one clinical trial reporting a benefit, which has limited generalizability. Case series report pancreatic duct stenting gives effective analgesia, but there are no clinical trials. Progress in understanding the mechanisms for pain and when this occurs in the natural history, together with assessing new therapies both pharmacological and endoscopic, will enable individualized care and may improve patients’ quality of life and survival.
Similar content being viewed by others
References
Globocan. Estimated cancer incidence, mortality and prevalence worldwide. 2012. http://globocan.iarc.fr/Pages/fact_sheets_population.aspx.
Pancreatic Cancer Research UK. 2014. http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/pancreatic-cancer/incidence#ref-0.
Freelove R, Waling AD. Pancreatic cancer: diagnosis and management. Am Fam Physician. 2006;73:485–492.
Moore JC, Adler DG. Celiac plexus neurolysis for pain relief in pancreatic cancer. Support Oncol. 2009;7:83–87.
Moningi S, Walker AJ, Hsu CC, et al. Correlation of clinical stage and performance status with quality of life in patients seen in a pancreas multidisciplinary clinic. J Oncol Pract. 2014;112:e216–e221.
Müller F, Köninger M, Wente H, Ceyhan B, Kleeff B. Factors influencing survival after bypass procedures in patients with advanced pancreatic adenocarcinomas. Am J Surg. 2008;195:221–228.
Barreto SG, Saccone GTP. Pancreatic nociception—revisiting the physiology and pathophysiology. Pancreatology. 2012;12:104–112.
Sharaiha R, Widmer J, Kahaleh K. Palliation of pancreatic ductal obstruction in pancreatic cancer. Gastrointest Endosc Clin N Am. 2013;23:917–923.
Wehrmann T, Riphaus F, Martchenko S. Endoscopic pancreatic duct stenting for relief of pancreatic cancer pain. Eur J Gastroenterol Hepatol. 2005;17:1395–1400.
Costamagna A, Palladino R, Mutignani M. Endoscopic pancreatic stenting in pancreatic cancer. Can J Gastroenterol. 1999;13:481–487.
Ceyhan GO, Bergmann F, Kadihasanoglu M, et al. Pancreatic neuropathy and neuropathic pain—a comprehensive pathomorphological study of 546 cases. Gastroenterology. 2009;136:177–186.
di Mola FF, di Sebastiano P. Pain and pain generation in pancreatic cancer. Langenbecks Arch Surg. 2008;393:919–922.
Hartel M, Di Mola FF, Selvaggi F, et al. Vanilloids in pancreatic cancer: potential for chemotherapy and pain management. Gut. 2006;55:519–528.
Demir IE, Schorn S, Schremmer-Danninger E, et al. Perineural mast cells are specifically enriched in pancreatic neuritis and neuropathic pain in pancreatic cancer and chronic pancreatitis. PLoS One. 2013;8:60529.
Hameed M, Hameed H, Erdek M. Pain management in pancreatic cancer. Cancers (Basel). 2010;3:43–60.
Esin E, Yalcin S. Neuropathic cancer pain: What we are dealing with? How to manage it? Oncol Targets Therapy. 2014;17:599–618.
Levy J, Wiersema J. Endoscopic ultrasound-guided celiac plexus and ganglia interventions. UptoDate. 2010. http://www.uptodate.com/contents/endoscopic-ultrasound-guided-celiac-plexus-and-ganglia-interventions.
Luz L, Al-Haddad M, DeWitt JA. EUS-guided celiac plexus interventions in pancreatic cancer pain: an update and controversies for the endosonographer. Endosc Ultrasound. 2014;3:213–220.
Nagels W, Pease N, Bekkering G, Cools F, Dobbels P. celiac plexus neurolysis for abdominal cancer pain: a systematic review. Pain Med Oxf J. 2013;14:1140–1163.
Kambadakone A, Thabet A, Gervais DA, Mueller PR, Arellano RS. CT-guided celiac plexus neurolysis: a review of anatomy, indications, technique, and tips for successful treatment. Radiographics. 2011;31:1599–1621.
Sahai AV, Lemelin V, Lam E, Paquin SC. Central vs. bilateral endoscopic ultrasound-guided celiac plexus block or neurolysis: a comparative study of short-term effectiveness. Am J Gastroenterol. 2009;104:326–329.
Sakamoto H, Kitano M, Kamata K, et al. EUS-guided broad plexus neurolysis over the superior mesenteric artery using a 25-gauge needle. Am J Gastroenterol. 2010;105:2599–2606.
Mittal KM. Pearls & oysters: acute spinal cord infarction following endoscopic ultrasound-guided celiac plexus neurolysis. Neurology. 2012;78:57–59.
Fujii L, Clain JE, Morris JM, Levy MJ. Anterior spinal cord infarction with permanent paralysis following endoscopic ultrasound celiac plexus neurolysis. Endoscopy. 2012;44:255–256.
Wyse JM, Carone M, Paquin SC, Usatii M, Sahai AV. Randomized, double-blind, controlled trial of early endoscopic ultrasound-guided celiac plexus neurolysis to prevent pain progression in patients with newly diagnosed, painful, inoperable pancreatic cancer. J Clin Oncol. 2011;29:3541–3546.
Puli SR, Reddy JBK, et al. EUS-guided celiac plexus neurolysis for pain due to chronic pancreatitis or pancreatic cancer pain: a meta-analysis and systematic review. Dig Dis Sci. 2009;54:2330–2337.
Kaufman M, Singh G, Das S, et al. Efficacy of endoscopic ultrasound-guided celiac plexus block and celiac plexus neurolysis for managing abdominal pain associated with chronic pancreatitis and pancreatic cancer. J Clin Gastroenterol. 2010;44:127–134.
Iwata K, Yasuda I, Enya M, et al. Predictive factors for pain relief after endoscopic ultrasound-guided celiac plexus neurolysis. Dig Endosc. 2011;23:140–145.
Ascunce G, Ribeiro A, Reis I, et al. EUS visualization and direct celiac ganglia neurolysis predicts better pain relief in patients with pancreatic malignancy. Gastrointest Endosc. 2011;73:267–274.
Kristensen A, Vagnildhaug OM, Grønberg BH, Kaasa S, Laird B, Solheim TS. Does chemotherapy improve health-related quality of life in advanced pancreatic cancer? A systematic review. J Oncol Haematol. 2016;99:286–298.
Gunaratnam NT, Sarma AV, Norton ID, Wiersema MJ. A prospective study of EUS-guided celiac plexus neurolysis for pancreatic cancer pain. Gastrointest Endosc. 2001;54:316–324.
Catalano MF, Ahmed U, Chauhan SS, Patel SN, Geenen JE. Celiac plexus neurolysis (CPN) in the treatment of refractory pain of pancreatic cancer (PCA): site specific response to therapy. Gastrointest Endosc. 2005;61:AB273.
Wiersema MJ, Wiersema LM. Endosonography-guided celiac plexus neurolysis. Gastrointest Endosc. 1996;44:656–662.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors have no conflicts of interest to disclose.
Rights and permissions
About this article
Cite this article
Koulouris, A.I., Banim, P. & Hart, A.R. Pain in Patients with Pancreatic Cancer: Prevalence, Mechanisms, Management and Future Developments. Dig Dis Sci 62, 861–870 (2017). https://doi.org/10.1007/s10620-017-4488-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10620-017-4488-z